title: Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.
abstract: Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and impaired glucose tolerance. We investigated whether metformin or changes in metabolic measurements (weight, fasting plasma glucose (FPG), or fasting insulin (FI)) improved serum alanine aminotransferase (ALT) activity, as a marker for NAFLD, in the Diabetes Prevention Program (DPP). From 1996 to 1999, 2,153 participants without marked elevations of serum ALT at baseline were randomized (1,081 to placebo, 1,072 to metformin) and treated for an average of 3.2 years. ALT increased during the first 2 years of the study, and was slightly but significantly lower in the participants randomized to metformin. In regression models adjusted for sex, baseline age, FPG, and FI, these differences remained significant, but disappeared after adjustment for weight, FPG, and FI changes at each examination. The 3-year cumulative incidence for development of abnormal ALT concentrations was not significantly different ((mean +/- s.e.) 21.4 +/- 1.4% and 24.6 +/- 1.4%, P = 0.11) in the metformin vs. placebo groups but was lower in individuals in both groups that lost more weight by the end of year 1 (metformin: 19.4 +/- 2.4% vs. 27.5 +/- 3.7%, for highest vs. lowest quartile of weight loss; placebo: 18.7 +/- 3.4% vs. 28.8 +/- 2.6%). Over 3 years of follow-up in persons at high risk for development of diabetes, serum ALT was consistently lower in those treated with metformin compared with placebo. This effect was mediated by weight loss, indicating that the effects of metformin therapy on ALT is via its effects on weight.
authors.affiliation: National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Krakoff
authors.forename: Jeanne M
authors.initials: JM
authors.lastname: Clark
authors.forename: Jill P
authors.initials: JP
authors.lastname: Crandall
authors.forename: Charlton
authors.initials: C
authors.lastname: Wilson
authors.forename: Mark E
authors.initials: ME
authors.lastname: Molitch
authors.forename: Frederick L
authors.initials: FL
authors.lastname: Brancati
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Edelstein
authors.forename: William C
authors.initials: WC
authors.lastname: Knowler
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D015415:Biomarkers; D003920:Diabetes Mellitus / Q000097:blood* / Q000517:prevention & control; D005234:Fatty Liver / Q000209:etiology; D005260:Female; D018149:Glucose Intolerance / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D015233:Models, Statistical; D050177:Overweight / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D012306:Risk; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology*
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D008687:Metformin; D000410:Alanine Transaminase